Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.79 |
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | KIT | P10721 | 7/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.64 |
| ▸ | CSF1R | P07333 | 4/20 | 0.64 |
| ▸ | FLT1 | P17948 | 3/20 | 0.64 |
| ▸ | FLT4 | P35916 | 3/20 | 0.64 |
| ▸ | TYK2 | P29597 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
| ▸ | TXK | P42681 | 2/20 | 0.64 |
| ▸ | SYK | P43405 | 2/20 | 0.64 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL159486 | 0.99 | BTK (0.77) | BTKKDRKITPDGFRACSF1R | |
| Hydrochloric Acid SCHEMBL935691 | 0.98 | BTK (0.76) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL4427732 | 0.97 | BTK (0.75) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL725543 | 0.92 | BTK (0.67) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL15973689 | 0.89 | BTK (0.62) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL12575010 | 0.88 | BTK (1.00) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL17135511 | 0.86 | BTK (0.58) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL28843997 | 0.86 | BTK (0.73) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL29884143 | 0.86 | BTK (0.73) | BTKKDRKITPDGFRACSF1R | |
| SCHEMBL29223177 | 0.85 | BTK (0.56) | BTKKDRKITPDGFRACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285622-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI AURORA BIOTECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | claimed |
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | claimed |
| EP-4378451-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Aurora Biotechnology Co., Ltd. (CN) | 2024-06-05 | — | — | EP | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| EP-4171534-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL Business Ltd (GB) | 2023-05-03 | — | — | EP | claimed |
| CN-115671110-A | Pazopanib oral pharmaceutical composition, preparation method and application thereof | 上海博志研新药物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2023006029-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海博志研新药物技术有限公司 | 2023-02-02 | — | — | WO | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| WO-2021260379-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2021-12-30 | — | — | WO | claimed |
| US-20200155594-A1 | HORNERIN: A NOVEL NON-VEGF MEDIATED ANGIOGENIC PROTEIN EXPRESSED IN BOTH HUMAN AND MOUSE ANGIOGENIC ENDOTHELIAL CELLS AND HUMAN PANCREATIC CANCER CELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-21 | — | — | US | claimed |
| EP-2608790-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-20130165456-A1 | COMBINATION | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | claimed |
| EP-2575460-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012106302-A1 | COMBINATION | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-08-09 | — | — | WO | claimed |
| WO-2012103276-A1 | COMBINATIONS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-08-02 | — | — | WO | claimed |
| WO-2012082337-A2 | COMBINATION | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-06-21 | — | — | WO | claimed |
| WO-2012055884-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | claimed |
| WO-2011150044-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165456-A1 | COMBINATION | PAICS, CA5A, CA5B | BTK 1020/4885KDR 3825/4885KIT 2555/4885 |
| US-20240285622-A1 | PAZOPANIB ORAL PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, JAK1 | BTK 355/4885KDR 149/4885KIT 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.